Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind Phase III Clinical Trial to Evaluate the Lot-to-lot Consistency of Three Consecutive Batches of Recombinant Herpes Zoster Vaccine (CHO Cell) Produced At a Commercial Scale in Subjects Aged 40 Years and Older.

NCT06654700 is registered in ClinicalTrials.gov with MAXVAX Biotechnology Limited Liability Company as lead sponsor.

NCT NCT06654700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06654700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind Phase III Clinical Trial to Evaluate the Lot-to-lot Consistency of Three Consecutive Batches of Recombinant Herpes Zoster Vaccine (CHO Cell) Produced At a Commercial Scale in Subjects Aged 40 Years and Older.
Lead sponsor
MAXVAX Biotechnology Limited Liability Company
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 9, 2024
Completion date
May 1, 2025
Enrollment
1,200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

herpes zoster